Skip to content

Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

A Preliminary Study of Prophylactic Fentanyl Pectin Nasal Spray (FPNS) for Exercise-Induced Breakthrough Dyspnea

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01832402
Enrollment
35
Registered
2013-04-16
Start date
2013-06-11
Completion date
2019-11-25
Last updated
2023-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Cancers

Keywords

Advanced Cancers, Exercise-Induced Breakthrough Dyspnea, Shortness of breath, Fentanyl pectin nasal spray, Placebo nasal spray, Walk test, Questionnaires, Surveys, Mental ability tests

Brief summary

The goal of this clinical research study is to learn if fentanyl nasal spray can help to control shortness of breath in patients who have been treated or are being treated for cancer. Fentanyl is commonly used for treatment of cancer pain. It may help patients with their shortness of breath as well. In this study, fentanyl will be compared to a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

Detailed description

Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to receive either fentanyl or placebo. You will have an equal chance of being assigned to either group. Neither you nor the study staff will know to which group you have been assigned. However, if needed for your safety, the study staff will be able to find out what you are receiving. Study Drug/Placebo Administration: Before you receive the study drug/placebo, you will walk back and forth in an indoor hallway for up to 6 minutes. You may feel out of breath or become exhausted. You may slow down, stop, and rest at any time you need to. After that, you will sit down and rest (for about 30 minutes). You will then be given the study drug/placebo by a nasal spray. You will then wait for another 20 minutes and repeat the walking test. After that, you will sit down and rest (for about 30 minutes). You will then be given the study drug/placebo again by a nasal spray. You will then wait for another 20 minutes and repeat the walking test for a third time. Study Visit: During your study visit, the study staff will collect information from your medical record about your age, sex, race, disease type, your performance status, any drugs you are taking, and possible causes of shortness of breath. Before each walk test, you will complete the questionnaires about your symptoms. Before and after each walk test, the study staff will record your heart rate, breathing rate, and the level of oxygen in your blood using a measuring device that will be clipped onto your finger. The study staff will also ask you 3 questions about how hard it is to catch your breath and your level of tiredness. During each walk test, you will be asked 6 times how hard it is to catch your breath. The distance you walked and how often and for how long you stopped will be recorded. Before and after the second and third walk tests, the study staff will ask you about any side effects from the study drug/placebo that you may be having. During the rest period between the walk tests, you may be asked several times how hard it is to catch your breath. After each walk test, you will also be asked to complete 4 tests of your mental abilities, including finger tapping, simple mathematics questions (addition, subtraction, multiplication, division), recall of numbers, and recall of objects. It should take 15 minutes to complete these tests. At the end of the study visit, you will complete 1 questionnaire that asks if you think the study drug/placebo is helping you, and how satisfied you are with the study. It should take about 5 minutes to complete the questionnaire. Length of Study: You will be on this study for up to 3 hours. You will be taken off study if intolerable side effects occur during the study. This is an investigational study. Fentanyl is FDA approved and commercially available for the treatment of pain. Its use to help with shortness of breath is investigational. Up to 25 patients will be enrolled in this study. All will be enrolled at MD Anderson.

Interventions

DRUGFentanyl Pectin Nasal Spray

Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.

DRUGPlacebo Nasal Spray

Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.

Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.

BEHAVIORALQuestionnaires

Questionnaires completed at baseline, before each walk test, and at end of final walk test.

Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.

Sponsors

Depomed
CollaboratorINDUSTRY
M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of cancer 2. Breakthrough dyspnea, defined in this study as dyspnea on exertion with an average intensity level \>=3/10 on the numeric rating scale 3. Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service or Thoracic Medical Oncology 4. Ambulatory and able to walk with or without walking aid 5. On strong opioids with morphine equivalent daily dose of 80-500 mg, with stable (i.e. +/- 30%) regular dose over the last 24 hours 6. Karnofsky performance status \>=50% 7. Age 18 or older 8. Able to complete study assessments

Exclusion criteria

1. Dyspnea at rest \>=7/10 at the time of enrollment 2. Supplemental oxygen requirement \>6 L per minute 3. Delirium (i.e. Memorial delirium rating scale \>13) 4. History of unstable angina or myocardial infarction 1 month prior to study enrollment 5. Resting heart rate \>120 at the time of study enrollment 6. Systolic pressure \>180 mmHg or diastolic pressure \>100 mmHg at the time of study enrollment 7. History of active opioid abuse within the past 12 months 8. History of allergy to fentanyl 9. Unwilling to provide informed consent 10. Patients who currently have no evidence of disease

Design outcomes

Primary

MeasureTime frameDescription
Dyspnea Numeric Rating Scale1.5 to 2 hours on a Single visitOur primary outcome was dyspnea intensity now using a dyspnea numeric rating scale that ranges from 0 (no shortness of breath) to 10 (worst possible shortness of breath). Measured the mean difference of dyspnea numeric rating scale between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests. 6 minute walk tests were carried out following guidelines from the American Thoracic Society.

Secondary

MeasureTime frameDescription
Dyspnea Borg Scale1.5 to 2 hours on a Single visitAssessed dyspnea using the modified Dyspnea Borg Scale that ranges from 0 (no shortness of breath) to 10 (worst possible shortness of breath). Measured the mean difference of modified Dyspnea Borg scale between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests.
Walk Distance at 6 Minutes1.5 to 2 hours on a Single visitCompared the mean difference of distance between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests.

Countries

United States

Participant flow

Recruitment details

Adult participants (age\>18) with an active diagnosis of cancer were recruited between 6/2013 and 3/2015 from the Supportive Care Center outpatient clinic of MD Anderson Cancer Center who satisfied the inclusion and exclusion criteria.

Participants by arm

ArmCount
Intervention Group (Fentanyl Pectin Nasal Spray)
Received Fentanyl Pectin Nasal Spray 20 minutes before 2nd and 3rd 6 minute walk tests, dose equivalent to 15-25% of total daily opioid dose each time.
12
Controlled Group (Placebo)
Received similar number of Placebo Spray 20 minutes before 2nd and 3rd 6 minute walk tests.
12
Total24

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeclining Performance status21
Overall StudyLost to Follow-up20
Overall StudyWithdrawal by Subject33

Baseline characteristics

CharacteristicTotalIntervention Group (Fentanyl Pectin Nasal Spray)Controlled Group (Placebo)
Age, Continuous52.4 Years51.5 Years53.3 Years
Cancer Stage
Localized/Locally advanced
6 Participants4 Participants2 Participants
Cancer Stage
Metastatic Stage
18 Participants8 Participants10 Participants
Cancer Type
Breast Cancer
5 Participants3 Participants2 Participants
Cancer Type
GastroIntestinal Cancer
6 Participants2 Participants4 Participants
Cancer Type
Genitourinary Cancer
2 Participants2 Participants0 Participants
Cancer Type
Gynecologic Cancer
2 Participants2 Participants0 Participants
Cancer Type
Hematologic
2 Participants0 Participants2 Participants
Cancer Type
Lung Cancer
3 Participants1 Participants2 Participants
Cancer Type
Others
4 Participants2 Participants2 Participants
Comorbidity
Asthma
5 Participants5 Participants0 Participants
Comorbidity
COPD
4 Participants2 Participants2 Participants
Comorbidity
Heart Failure
1 Participants1 Participants0 Participants
Education
Advanced Degree
3 Participants0 Participants3 Participants
Education
College
15 Participants8 Participants7 Participants
Education
High School or less
6 Participants4 Participants2 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants1 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
21 Participants11 Participants10 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
5 Participants3 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
19 Participants9 Participants10 Participants
Region of Enrollment
United States
24 participants12 participants12 participants
Sex: Female, Male
Female
13 Participants9 Participants4 Participants
Sex: Female, Male
Male
11 Participants3 Participants8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 120 / 120 / 120 / 12
other
Total, other adverse events
2 / 122 / 125 / 125 / 12
serious
Total, serious adverse events
0 / 120 / 120 / 120 / 12

Outcome results

Primary

Dyspnea Numeric Rating Scale

Our primary outcome was dyspnea intensity now using a dyspnea numeric rating scale that ranges from 0 (no shortness of breath) to 10 (worst possible shortness of breath). Measured the mean difference of dyspnea numeric rating scale between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests. 6 minute walk tests were carried out following guidelines from the American Thoracic Society.

Time frame: 1.5 to 2 hours on a Single visit

ArmMeasureGroupValue (MEAN)
Intervention Group (Fentanyl Pectin Nasal Spray)Dyspnea Numeric Rating ScaleMean difference between 1st and 2nd walk tests-2.0 score on a scale
Intervention Group (Fentanyl Pectin Nasal Spray)Dyspnea Numeric Rating ScaleMean difference between 1st and 3rd walk tests-2.3 score on a scale
Controlled Group (Placebo)Dyspnea Numeric Rating ScaleMean difference between 1st and 2nd walk tests-1.7 score on a scale
Controlled Group (Placebo)Dyspnea Numeric Rating ScaleMean difference between 1st and 3rd walk tests-2.5 score on a scale
Secondary

Dyspnea Borg Scale

Assessed dyspnea using the modified Dyspnea Borg Scale that ranges from 0 (no shortness of breath) to 10 (worst possible shortness of breath). Measured the mean difference of modified Dyspnea Borg scale between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests.

Time frame: 1.5 to 2 hours on a Single visit

ArmMeasureGroupValue (MEAN)
Intervention Group (Fentanyl Pectin Nasal Spray)Dyspnea Borg ScaleMean difference between 1st and 2nd walk tests-1.8 score on a scale
Intervention Group (Fentanyl Pectin Nasal Spray)Dyspnea Borg ScaleMean difference between 1st and 3rd walk tests-1.7 score on a scale
Controlled Group (Placebo)Dyspnea Borg ScaleMean difference between 1st and 2nd walk tests-1.7 score on a scale
Controlled Group (Placebo)Dyspnea Borg ScaleMean difference between 1st and 3rd walk tests-2.4 score on a scale
Secondary

Walk Distance at 6 Minutes

Compared the mean difference of distance between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests.

Time frame: 1.5 to 2 hours on a Single visit

ArmMeasureGroupValue (MEAN)
Intervention Group (Fentanyl Pectin Nasal Spray)Walk Distance at 6 MinutesMean difference between 1st and 2nd walk tests23.8 meters
Intervention Group (Fentanyl Pectin Nasal Spray)Walk Distance at 6 MinutesMean difference between 1st and 3rd walk tests23.3 meters
Controlled Group (Placebo)Walk Distance at 6 MinutesMean difference between 1st and 2nd walk tests16.3 meters
Controlled Group (Placebo)Walk Distance at 6 MinutesMean difference between 1st and 3rd walk tests14.6 meters

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026